Reversibility of Bronchial Obstruction in Children Born Preterm
Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Oct 29, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different inhaled medications can help improve breathing in children who were born prematurely and have a condition called Chronic Lung Disease of Immaturity (CLDI), which can cause bronchial obstruction (narrowing of the airways). The researchers want to find out if one type of inhaled medication works better than others, or if a combination of medications is more effective in helping these children breathe easier.
To be eligible for the study, children need to be born before 35 weeks of pregnancy and diagnosed with CLDI and bronchial obstruction, confirmed by a breathing test called spirometry. Participants will visit the clinic three times, each time receiving a different inhaled medication (either a beta2-agonist, an anticholinergic, or a combination of both). Before and after taking the medication, they will perform a breathing test to see how well their airways respond. The trial is currently recruiting participants, and it’s important that children are stable and not experiencing any acute infections during their visits.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • children born preterm /before the 35th week of gestational age (35+0)/
- • all subjects must have chronic lung disease of prematurity with bronchial obstruction, confirmed by spirometry
- • subjects must be able to cooperate well in spirometry
- Exclusion Criteria:
- • The presence of another chronic respiratory disease (e.g., cystic fibrosis, primary ciliary dyskinesia, etc.). Asthma bronchiale is not an exclusion criterion, but subjects with CLDI combined with asthma bronchiale represent a specific subgroup of subjects and we perform a standardized therapeutic test with inhaled corticosteroids (ICS) administered for at least 12 weeks via a pressurized aerosol dispenser (pMDI) via an inhaler attachment before enrollement.
- • Insufficient cooperation during spirometry.
About Charles University, Czech Republic
Charles University, located in the Czech Republic, is a prestigious institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct innovative research that aims to improve patient outcomes and contribute to the global medical community. With a focus on ethical standards and rigorous scientific methodologies, Charles University collaborates with various stakeholders to explore new therapies and enhance healthcare practices, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Prague, , Czechia
Patients applied
Trial Officials
Jana Tukova, MD,PhD
Principal Investigator
Charles University, Czech Republic First Faculty of Medicine, Prague
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported